Royalty Pharma (RPRX) Minority Interest (2019 - 2026)
Royalty Pharma (RPRX) posted Minority Interest of $3.0 billion for Q1 2026, down 5.86% sequentially from $3.2 billion in Q4 2025, and down 1.67% YoY from $3.1 billion in Q1 2025.
Royalty Pharma (RPRX) Minority Interest (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Minority Interest for 8 years, with the latest figure at $3.0 billion in Q1 2026.
- Quarterly Minority Interest fell 1.67% year-over-year to $3.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (down 1.67% YoY) and the FY2025 annual result came in at $3.2 billion, down 4.65% from the prior year.
- Minority Interest retreated to $3.0 billion in Q1 2026 per RPRX's latest filing, from $3.2 billion in the prior quarter.
- Over five years, Minority Interest peaked at $4.4 billion in Q2 2022 and troughed at $3.0 billion in Q1 2026.
- A 5-year average of $3.6 billion and a median of $3.4 billion in 2024 frame the typical range for Minority Interest.
- The sharpest annual moves came in 2023 and 2026: Minority Interest slipped 19.38% in 2023, then slipped 1.67% in 2026.
- Over 5 years, Minority Interest stood at $3.9 billion in 2022, then fell by 8.71% to $3.6 billion in 2023, then slipped by 4.55% to $3.4 billion in 2024, then declined by 4.65% to $3.2 billion in 2025, then dropped by 5.86% to $3.0 billion in 2026.
- According to Business Quant data, Minority Interest over the past three periods registered $3.0 billion, $3.2 billion, and $3.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.95 Bn |
| Mar 31, 2026 | 3.05 Bn |
| Dec 31, 2025 | 3.24 Bn |
| Sep 30, 2025 | 3.21 Bn |
| Jun 30, 2025 | 3.16 Bn |
| Mar 31, 2025 | 3.10 Bn |
| Dec 31, 2024 | 3.40 Bn |
| Sep 30, 2024 | 3.39 Bn |
| Jun 30, 2024 | 3.28 Bn |
| Mar 31, 2024 | 3.36 Bn |
| Dec 31, 2023 | 3.56 Bn |
| Sep 30, 2023 | 3.45 Bn |
| Jun 30, 2023 | 3.53 Bn |
| Mar 31, 2023 | 3.87 Bn |
| Dec 31, 2022 | 3.90 Bn |
| Sep 30, 2022 | 4.26 Bn |
| Jun 30, 2022 | 4.38 Bn |
| Mar 31, 2022 | 4.36 Bn |
| Dec 31, 2021 | 4.47 Bn |
| Sep 30, 2021 | 4.59 Bn |